NCT03137121: Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients

NCT03137121
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2|Phase 3
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with a history of CNS disease (e.g. brain metastases, seizure disorder); Patients with planned chemotherapy or radiation during the 7 days following study initiation
https://ClinicalTrials.gov/show/NCT03137121

Comments are closed.

Up ↑